[go: up one dir, main page]

AR065039A1 - Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso - Google Patents

Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso

Info

Publication number
AR065039A1
AR065039A1 ARP080100316A ARP080100316A AR065039A1 AR 065039 A1 AR065039 A1 AR 065039A1 AR P080100316 A ARP080100316 A AR P080100316A AR P080100316 A ARP080100316 A AR P080100316A AR 065039 A1 AR065039 A1 AR 065039A1
Authority
AR
Argentina
Prior art keywords
release
weight
active agent
composition
amount
Prior art date
Application number
ARP080100316A
Other languages
English (en)
Inventor
Sanjay Boldhane
Kour Chand Jindal
Rajesh Jain
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39644166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065039(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of AR065039A1 publication Critical patent/AR065039A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas de liberacion modificada que comprenden por lo menos un agente(s) farmacéuticamente activo(s) que posee una solubilidad que depende del pH, por lo menos un polímero(s) controlador de la tasa de liberacion que predominantemente controla la liberacion de agente(s) activos en un medio acídico, un sistema modificador de la tasa de liberacion que controla la liberacion del agente(s) activo(s) en medios acídicos y básicos, y opcionalmente uno o más de otros excipientes farmacéuticamente aceptables. También se provee un proceso para la preparacion de tales composiciones y el método para su utilizacion. Las composiciones de liberacion modificada de la presente invencion son de utilidad para proveer niveles profilácticamente o terapéuticamente eficaces de agente(s) activo(s) durante un período de tiempo prolongado. Reivindicacion 1: Una composicion farmacéutica de liberacion modificada caracterizada porque comprende al menos un agente(s) farmacéuticamente activo que tiene una solubilidad dependiente del pH, un polímero controlador de la lasa de liberacion que predominantemente controla la liberacion del agente activo en un medio acídico en una cantidad de 3-80% peso/peso de la composicion, un sistema modificador de la tasa de liberacion que controla la liberacion del agente activo en los medios acídicos y básicos que consiste en una combinacion de al menos un agente gelificante in situ en una cantidad no menor de aproximadamente 0,5% peso/peso de la composicion, al menos un agente facilitador de la gelacion en una cantidad de 2-17,5% peso/peso de la composicion y opcionalmente al menos un polímero controlador de la tasa independiente del pH en una cantidad de hasta 40% peso/peso de la composicion y opcionalmente uno o más de otros excipientes farmacéuticamente aceptables.
ARP080100316A 2007-01-25 2008-01-25 Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso AR065039A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN164DE2007 2007-01-25

Publications (1)

Publication Number Publication Date
AR065039A1 true AR065039A1 (es) 2009-05-13

Family

ID=39644166

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100316A AR065039A1 (es) 2007-01-25 2008-01-25 Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso

Country Status (11)

Country Link
US (1) US20100056493A1 (es)
EP (1) EP2114380A1 (es)
JP (1) JP2010532746A (es)
KR (1) KR20090109113A (es)
CN (1) CN101588794A (es)
AR (1) AR065039A1 (es)
BR (1) BRPI0807807A2 (es)
CL (1) CL2008000219A1 (es)
MX (1) MX2009007913A (es)
RU (1) RU2009131931A (es)
WO (1) WO2008090569A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087490A1 (en) 2007-06-08 2009-04-02 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
EP2268283A2 (en) * 2008-03-12 2011-01-05 Dexcel Ltd. Oral modified-release formulations containing thiazepines
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
WO2010001413A2 (en) * 2008-07-01 2010-01-07 Lupin Limited Sustained release pharmaceutical compositions comprising quetiapine
DE102008046650A1 (de) * 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
EP2355804A1 (en) * 2008-11-26 2011-08-17 Krka Quetiapine composition
AT10562U3 (de) * 2008-12-05 2010-01-15 Aop Orphan Pharmaceuticals Ag Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie
EP2373319B1 (en) * 2009-01-05 2013-07-31 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010089259A2 (en) * 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
EP2233130A1 (en) * 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
CN102151242B (zh) * 2010-02-11 2012-10-31 中国医学科学院药用植物研究所 一种抗结核药物的原位凝胶缓释制剂及其制备方法
ME02118B (me) * 2010-03-25 2015-10-20 Aop Orphan Pharmaceuticals Ag Nova kompozicija za tretman esencijalne trombocitemije
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
WO2011154118A1 (en) 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
CN102939300A (zh) 2010-06-07 2013-02-20 泰立克公司 无溶剂化晶体依泽替米贝盐酸盐d型的制备
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
CN102917694A (zh) 2010-06-07 2013-02-06 泰立克公司 依泽替米贝的片剂制剂
CN102525983A (zh) * 2010-12-31 2012-07-04 北京万全阳光医药科技有限公司 胍法新缓释片及其制备方法
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
CN102335155B (zh) * 2011-10-17 2013-03-27 苏州大学 一种富马酸喹硫平缓释片及其制备方法
CN102579381B (zh) * 2012-03-30 2013-07-10 河南中帅医药科技发展有限公司 盐酸胍法辛缓释制剂及其制备方法
US9271937B2 (en) * 2012-05-31 2016-03-01 Covidien Lp Oxidized cellulose microspheres
KR101462065B1 (ko) * 2012-12-14 2014-11-14 박재돈 구안파신 함유 경구용 서방성 약제학적 조성물
ES2619121T3 (es) 2013-03-15 2017-06-23 Warner Chilcott Company, Llc Forma farmacéutica de dosificación en cápsula de gelatina blanda con goma guar modificada
JP6165970B2 (ja) * 2013-05-02 2017-07-19 カ−ディオノブーム ゲーエムベーハー バルーン表面被覆
EP3307248A1 (en) * 2015-06-10 2018-04-18 Disphar International B.V. Improved pharmaceutical formulation
CN106038506A (zh) * 2016-07-20 2016-10-26 南京正宽医药科技有限公司 一种富马酸喹硫平片及其制备方法
KR20180062063A (ko) * 2016-11-30 2018-06-08 (주) 메티메디제약 서방형 항암용 약학 조성물
CA3054817A1 (en) * 2017-03-13 2018-09-20 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
US10835489B2 (en) 2018-03-09 2020-11-17 University Of Saskatchewan Modified release formulations of mycophenolate mofetil
CN115120590B (zh) * 2022-06-07 2024-12-27 复旦大学 一种以难溶盐为pH调节剂的凝胶缓释制剂及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
MX2008000084A (es) * 2005-06-29 2008-03-18 Panacea Biotec Ltd Composiciones farmaceuticas de liberacion sostenida y procedimientos de las mismas.

Also Published As

Publication number Publication date
JP2010532746A (ja) 2010-10-14
CN101588794A (zh) 2009-11-25
BRPI0807807A2 (pt) 2014-06-17
KR20090109113A (ko) 2009-10-19
CL2008000219A1 (es) 2008-05-16
MX2009007913A (es) 2009-07-31
RU2009131931A (ru) 2011-02-27
WO2008090569A1 (en) 2008-07-31
US20100056493A1 (en) 2010-03-04
EP2114380A1 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
AR065039A1 (es) Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso
AR058620A1 (es) Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
MX2009003735A (es) Composicion en deposito inyectable y su procedimiento de preparacion.
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
NZ604026A (en) Injectable flowable composition comprising buprenorphine
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
GT200700034A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
BRPI0611400B8 (pt) formulações contendo xiloglicano muco-adesivas úteis em dispositivos médicos e em formulações farmacêuticas
UY31957A (es) Metodo anticonceptivo mejorado
PE20040418A1 (es) Nuevas formulaciones farmaceuticas solidas que comprenden telmisartano y su preparacion
WO2007084460A8 (en) Pharmaceutical compositions with enhanced stability
PE20080374A1 (es) Composiciones farmaceuticas de ropinirol
PE20080423A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
PL1750862T3 (pl) Kompozycja farmaceutyczna zawierająca irbesartan
RU2011136636A (ru) Фармацевтическая композиция для орального введения
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
CY1114311T1 (el) Θεραπευτικα συστηματα αμεσης απελευθερωσης για βελτιωμενη απο του στοματος απορροφηση 7-[(ε)-τριτ-βουτυλοξυιμινομεθυλο]καμπτοθεκινης
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
UY31343A1 (es) Composicion con una combinacion de principios activos para el tratamiento del estrenimiento
WO2004078111A3 (en) Extended release minocycline compositions and processes for their preparation

Legal Events

Date Code Title Description
FA Abandonment or withdrawal